China Biotech Services Holdings (HKSE:08037) Mohanram G-Score: 3 (As of Dec. 2025) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08037 China Biotech Services Holdings Ltd HKSE:08037
19 GF Score
Price HK$0.64
GF Value HK$0.27
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is China Biotech Services Holdings Mohanram G-Score?

China Biotech Services Holdings HKSE:08037 -1.54% 19 Mohanram G-Score is 3 as of Dec. 2025, which is 50% above its 10-year median of 2.00. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

China Biotech Services Holdings has an G-score of 3.

The historical rank and industry rank for China Biotech Services Holdings's Mohanram G-Score or its related term are showing as below:

HKSE:08037' s Mohanram G-Score Range Over the Past 10 Years
Min: 0   Med: 2   Max: 5
Current: 3

During the past 13 years, the highest Piotroski G-score of China Biotech Services Holdings was 5. The lowest was 0. And the median was 2.

China Biotech Services Holdings  (HKSE:08037) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


China Biotech Services Holdings Mohanram G-Score Related Terms


China Biotech Services Holdings Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for China Biotech Services Holdings's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings Mohanram G-Score Chart

China Biotech Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 3.00 3.00 3.00

China Biotech Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 N/A 3.00 N/A 3.00

HKSE:08037 vs TMO, DHR, IDXX: Mohanram G-Score Comparison

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biotech Services Holdings Mohanram G-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Mohanram G-Score falls into.


HKSE:08037
19GF Score
China Biotech Services Holdings Ltd HKSE:08037
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Biotech Services Holdings Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

China Biotech Services Holdings has an G-score of 3.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 3 mean?
China Biotech Services Holdings (HKSE:08037) has a Mohanram G-Score of 3 as of Dec. 2025. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on China Biotech Services Holdings and its competitors. This is 50% above median its historical median of 2.00.
Is China Biotech Services Holdings' Mohanram G-Score too high?
China Biotech Services Holdings' current Mohanram G-Score of 3 is 50% above median its 10-year median of 2.00. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Mohanram G-Score compare to TMO and DHR?
China Biotech Services Holdings' Mohanram G-Score of 3 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Medical Diagnostics & Research company?
A good Mohanram G-Score depends on the Medical Diagnostics & Research industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on China Biotech Services Holdings and its competitors. China Biotech Services Holdings's current Mohanram G-Score is 3, which is 50% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Mohanram G-Score is 3, which is 50% above median its 10-year median of 2.00. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Mohanram G-Score is 3 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?

Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued. The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27. GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08037:

  • Mohanram G-Score: 3 (50% above median its 10-year median of 2.00)
  • GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
  • GF Score™: 19/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Biotech Services Holdings Business Description

Address 255-257 Gloucester Road, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score

Get the complete analysis for HKSE:08037

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.64
Price
HK$0.27
GF Value